Compare · DXCM vs SRDX
DXCM vs SRDX
Side-by-side comparison of DexCom Inc. (DXCM) and Surmodics Inc. (SRDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SRDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 47.0x SRDX ($598.4M).
- Over the past year, DXCM is down 14.9% and SRDX is up 47.8% - SRDX leads by 62.8 points.
- DXCM has hit the wire 26 times in the past 4 weeks while SRDX has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 7 for SRDX).
- Company
- DexCom Inc.
- Surmodics Inc.
- Price
- $72.84+0.38%
- $42.99+0.33%
- Market cap
- $28.11B
- $598.4M
- 1M return
- +20.73%
- +52.83%
- 1Y return
- -14.94%
- +47.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1998
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 7
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Surmodics Inc.
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest SRDX
- SEC Form 15-12G filed by Surmodics Inc.
- SEC Form EFFECT filed by Surmodics Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Surmodics Inc.
- SVP, Medical Device Coatings Olson Charles W returned 52,278 shares to the company, closing all direct ownership in the company (SEC Form 4)
- VP Finance, Corp. Controller Manders John D. returned 8,155 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Sr. VP of Legal, GC and Sec. Weber Gordon S. returned 21,040 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Vascular Interventions Sides Teri Woodwick returned 34,703 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Dantzker David returned 40,183 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Heine Lisa Wipperman returned 13,978 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Knight Susan E returned 37,240 shares to the company, closing all direct ownership in the company (SEC Form 4)